< Back to Results
A Randomized, Double-blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate CancerUnique Dataset IDProstat_AmgenI_2006_121ClinicalTrial.gov IDNCT00321620
Clinical Trial Title
A Randomized, Double-blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer
Trial Summary and Conditions
Bone complications associated with cancer arise from increased bone resorption and include bone pain, pathologic bone fractures, nerve compression, and hypercalcemia. Accumulating evidence suggests that most pathologic bone resorption relies on the RANK/RANKL pathway, which regulates the differentiation, survival, and activation of osteoclasts. Another key component of RANK/RANKL pathway is OPG, an endogenous decoy receptor that binds and neutralizes RANKL. The antiresorptive property of OPG has been demonstrated in murine models of hypercalcemia of malignancy and metastatic bone destruction. According to recent findings, it appears that maximum anti-resorptive effects due to RANKL-RANK pathway inhibition are more pronounced than those due to bisphosphonates.
These datasets are analysis datasets that bear some resemblance to CDISC ADaM standards. These datasets has been subsetted to include data from only the comparator arm of this clinical trial.
PRIMARY OBJECTIVE To determine if denosumab is non-inferior to zoledronic acid (Zometa) with respect to the first on-study occurrence of a skeletal-related event (SRE) in subjects with hormone-refractory prostate cancer and bone metastases. SRE is defined as pathological fracture (vertebral or nonvertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. SECONDARY OBJECTIVES - To determine if denosumab is superior to zoledronic acid with respect to first on-study SRE - To determine if denosumab is superior to zoledronic acid with respect to first-and-subsequent on-study SRE (multiple event analysis) - to assess the safety and tolerability of denosumab compared with zoledronic acid
Outcomes documented in the protocol
To gain access to the data and analytic tools click here.
PROTOCOL: Amgen 20050103 Protocol.pdf
CRF: Amgen 20050103 CRF.pdf
DATA DICTIONARY: Amgen 20050103 DDT.pdf
DATA (COMPARATOR ARM): Amgen 20050103 SAS datasets.zip